3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
15
Fallopian Tube Neoplasms
13
Lung Neoplasms
11
Melanoma
8
Colorectal Neoplasms
8
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
7
Carcinoma, Hepatocellular
7
Urinary Bladder Neoplasms
6
Carcinoma, Renal Cell
6
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Brain Neoplasms
4
Rectal Neoplasms
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Uveal Melanoma
2
Thyroid Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Oligodendroglioma
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, B-Cell
2
Lymphoma
2
Interventions
Doxorubicin
6
Trabectedin
5
pazopanib
4
Radiotherapy
4
ribociclib
3
pembrolizumab
3
palbociclib
3
Gemcitabine
3
brostallicin
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Immunoglobulin G
2
Imatinib Mesylate
2
Ifosfamide
2
Docetaxel
2
Dexamethasone
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
tanespimycin
1
talimogene laherparepvec
1
sotigalimab
1
soblidotin
1
sitravatinib
1
saracatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liposarcoma
×
Disulfides
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled